Pipeline
Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics.
Indication
Product Candidate
Discovery
Pre-IND
IND Enabling
Phase 1
Retinitis Pigmentosa
Genotype agnostic
RAY-001
Pre-IND
Other Inherited retinal diseases
Choroideremia
Stargardt’s disease
RAY-001
Discovery
Geographic Atrophy
RAY-002
Discovery